A5041049090- Heart Failure Treatment and Management
- Cardiovascular Function and Risk Factors
- Cardiac pacing and defibrillation studies
- Diabetes Treatment and Management
- Erythropoietin and Anemia Treatment
- Chronic Disease Management Strategies
- Potassium and Related Disorders
- Health Systems, Economic Evaluations, Quality of Life
- Heart Rate Variability and Autonomic Control
- Cardiac Arrhythmias and Treatments
- Iron Metabolism and Disorders
- Mechanical Circulatory Support Devices
- Cardiac electrophysiology and arrhythmias
- Pharmaceutical Practices and Patient Outcomes
- Blood Pressure and Hypertension Studies
- Cardiac Health and Mental Health
- Atrial Fibrillation Management and Outcomes
- Heart rate and cardiovascular health
- Venous Thromboembolism Diagnosis and Management
- Pharmaceutical Economics and Policy
- Acute Myocardial Infarction Research
- Cardiac Valve Diseases and Treatments
- Medication Adherence and Compliance
- Obstructive Sleep Apnea Research
- Transplantation: Methods and Outcomes
Concord Repatriation General Hospital
2016-2025
The University of Sydney
2016-2025
Pfizer (United Kingdom)
2023
Roche (Switzerland)
2023
Servier (France)
2023
Sanofi (Belgium)
2023
Philips (United Kingdom)
2023
Boehringer Ingelheim (Australia)
2023
Medtronic (Ireland)
2023
Terumo (Germany)
2023
Chronic heart failure (CHF) is found in 1.5%–2.0% of Australians. Considered rare people aged less than 45 years, its prevalence increases to over 10% ≥ 65 years. CHF one the most common reasons for hospital admission and general practitioner consultation elderly (≥ 70 years). Common causes are ischaemic disease (present > 50% new cases), hypertension (about two-thirds cases) idiopathic dilated cardiomyopathy (around 5%–10% cases). Diagnosis based on clinical features, chest x-ray objective...
Chronic heart failure (CHF) is a complex and lethal clinical syndrome accounting for an increasing number of Australian hospital separations more than 2700 deaths in 2008. In 2006, the National Heart Foundation Australia Cardiac Society New Zealand published Guidelines prevention, detection management chronic Australia, 2006. Results from recently trials provide additional information to be considered CHF. some cases, this new evidence strengthens recommendations previously made 2006...
<h3>Importance</h3> The period following heart failure hospitalization (HFH) is a vulnerable time with high rates of death or recurrent HFH. <h3>Objective</h3> To evaluate clinical characteristics, outcomes, and treatment response to vericiguat according prespecified index event subgroups from HFH in the Vericiguat Global Study Subjects With Heart Failure Reduced Ejection Fraction (VICTORIA) trial. <h3>Design, Setting, Participants</h3> Analysis an international, randomized,...
Abstract Objective To examine associations between remoteness of region residence and in‐hospital mortality for people admitted to hospital with heart failure in New South Wales during 2002–21. Study design Retrospective observational cohort study; analysis Admitted Patient Data Collection data. Setting, participants Adult (16 years or older) NSW residents public hospitals, 1 January 2002 – 30 September 2021. Only first admissions the study period were included. Main outcome measures...
This consensus statement of Australian clinicians provides new recommendations for the pharmacological management heart failure based on studies reported since publication 2018 guidelines.▪Use sodium-glucose cotransporter 2 (SGLT2) inhibitors to prevent hospitalisation in type diabetes mellitus can be extended patients with multiple cardiovascular risk factors, albuminuric chronic kidney disease, or atherosclerotic disease. ▪New evidence supports use a mineralocorticoid receptor antagonist...
Heart failure (HF) is a clinical syndrome that secondary to an abnormality of cardiac structure or function. These practice guidelines focus on the diagnosis and management HF with recommendations have been graded strength evidence likely absolute benefit versus harm. Additional considerations are presented as points. Main recommendations: Blood pressure lipid lowering decrease risk developing HF. Sodium-glucose cotransporter 2 inhibitors hospitalisation in patients type diabetes...
Objective The global burden of HFpEF is high and, despite developments in available therapies, patient outcomes have not improved significantly. This study aimed to explore the optimal approaches diagnosis and treatment patients with develop recommendations on how guideline directed medical therapy can be introduced a more equitable universal manner.
Inconsistencies in healthcare access, varying infrastructure, resource constraints and diverse local practices as well practical political issues restrict the global applicability of currently available guidelines. There is a need for universal recommendations that address unique challenges faced by patients providers worldwide. Our iCARDIO Alliance Global Implementation Guidelines emphasize incorporation novel therapies, while integrating standard care with most uptodate evidence to enable...
Diabetes mellitus is associated with significant morbidity and premature mortality for which heart failure (HF) a major cause. HF may be due to ischaemia, hypertension, uraemia, or specific diabetic cardiomyopathy (DCM), multiple causes co-exist. A recent systematic review suggests that >40% of people type 2 diabetes have diastolic dysfunction without reduction cardiac systolic function. In 1 known cardiovascular disease, 16% had dysfunction. Early DCM asymptomatic can progress symptomatic...
In the Asia-Pacific region, heart failure (HF) is associated with significant health and socioeconomic burden. Given differences in epidemiology of HF, as well availability healthcare resources between Asian Western countries, an Pacific Society Cardiology (APSC) working group developed consensus recommendations on management chronic HF region. The APSC expert panel reviewed appraised available evidence using Grading Recommendations Assessment, Development Evaluation (GRADE) system....
Abstract Aims Heart failure (HF) causes significant morbidity and mortality, but the rates characteristics of people with HF in Australia are not well studied. SHAPE set out to describe patients seen real‐world setting. Methods We analysed anonymized patient data extracted from clinical software 43 participating GP clinics for 5 year period 1 July 2013 30 June 2018. Patients were stratified into ‘definite’ ‘probable’ based on a hierarchy selection criteria their characteristics. Symptoms...